Patients with atopic dermatitis who receive treatment with dupilumab may be at an increased risk for new-onset vitiligo.
Among patients with AD, GLP-1 RAs reduced the risk for various MACE outcomes, including heart failure, cerebrovascular disease, and more.
Enveda, a clinical-stage biotech company developing first-in-class small-molecules derived from life’s chemistry, today ...
Dr. Lee was compensated for her participation. Board-certified dermatologist Sandra Lee, M.D. (yes, "Dr. Pimple Popper" herself) has spent years helping patients navigate complex skin conditions.
As the 2026 American Academy of Dermatology (AAD) annual meeting continues in Denver, MedPage Today is offering another ...
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...
In patients with moderate atopic dermatitis, the use of Opzelura (ruxolitinib) led to early and sustained improvements in ...
PATIENTS with moderate-to-severe atopic dermatitis showed generally low long-term upadacitinib safety event rates across ages. Upadacitinib Safety in Atopic Dermatitis Across Age ...
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the ...
A topic dermatitis is a chronic condition that tends to rear its itchy head during certain periods before subsiding — for months, possibly, or even years. It particularly affects the insides of the ...
New research links atopic dermatitis to S1P signalling pathways driving inflammation. Learn how this could shape future ...
Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results